Great Lakes Advisors LLC Invests $3.56 Million in Tango Therapeutics, Inc. $TNGX

Great Lakes Advisors LLC purchased a new stake in Tango Therapeutics, Inc. (NASDAQ:TNGX) during the 3rd quarter, according to its most recent Form 13F filing with the SEC. The institutional investor purchased 423,851 shares of the company’s stock, valued at approximately $3,560,000. Great Lakes Advisors LLC owned 0.38% of Tango Therapeutics as of its most recent SEC filing.

A number of other institutional investors have also recently modified their holdings of TNGX. CWM LLC grew its position in Tango Therapeutics by 182.2% in the second quarter. CWM LLC now owns 4,905 shares of the company’s stock valued at $25,000 after acquiring an additional 3,167 shares during the last quarter. Dynamic Technology Lab Private Ltd increased its holdings in Tango Therapeutics by 139.7% during the 1st quarter. Dynamic Technology Lab Private Ltd now owns 25,801 shares of the company’s stock worth $35,000 after purchasing an additional 15,037 shares in the last quarter. Legal & General Group Plc increased its stake in Tango Therapeutics by 30.7% in the 2nd quarter. Legal & General Group Plc now owns 6,985 shares of the company’s stock valued at $36,000 after buying an additional 1,640 shares during the last quarter. Ameritas Investment Partners Inc. increased its holdings in Tango Therapeutics by 78.8% during the second quarter. Ameritas Investment Partners Inc. now owns 7,830 shares of the company’s stock worth $40,000 after buying an additional 3,452 shares during the last quarter. Finally, Tower Research Capital LLC TRC increased its stake in shares of Tango Therapeutics by 44.3% in the second quarter. Tower Research Capital LLC TRC now owns 9,473 shares of the company’s stock worth $49,000 after purchasing an additional 2,907 shares in the last quarter. 78.99% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

A number of research firms have recently issued reports on TNGX. Wolfe Research began coverage on Tango Therapeutics in a report on Tuesday, November 18th. They issued a “peer perform” rating for the company. Piper Sandler upped their target price on shares of Tango Therapeutics from $11.00 to $14.00 and gave the stock an “overweight” rating in a research note on Friday, January 16th. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Tango Therapeutics in a research report on Wednesday, January 21st. Guggenheim boosted their price objective on shares of Tango Therapeutics from $10.00 to $12.00 and gave the company a “buy” rating in a research report on Friday, October 24th. Finally, B. Riley upped their target price on shares of Tango Therapeutics from $8.00 to $14.00 and gave the stock a “buy” rating in a report on Tuesday, November 18th. Six investment analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus price target of $13.60.

Tango Therapeutics Stock Performance

Tango Therapeutics stock opened at $11.61 on Friday. The company has a market capitalization of $1.56 billion, a PE ratio of -12.48 and a beta of 1.75. Tango Therapeutics, Inc. has a fifty-two week low of $1.03 and a fifty-two week high of $13.46. The company has a 50 day moving average price of $10.24 and a 200-day moving average price of $8.39.

Tango Therapeutics (NASDAQ:TNGX) last issued its quarterly earnings data on Tuesday, November 4th. The company reported $0.13 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.01 by $0.12. Tango Therapeutics had a negative net margin of 151.15% and a negative return on equity of 60.80%. The company had revenue of $53.81 million for the quarter, compared to analyst estimates of $41.35 million. On average, analysts forecast that Tango Therapeutics, Inc. will post -1.19 earnings per share for the current year.

Tango Therapeutics Profile

Tango Therapeutics is a clinical-stage biotechnology company dedicated to developing precision medicines that exploit genetic vulnerabilities in cancer cells. Leveraging a proprietary synthetic lethality platform, the company identifies and targets tumor-specific dependencies in DNA damage response and related pathways. By focusing on tumor cell collateral sensitivities, Tango aims to bring differentiated small-molecule therapies to patients with genetic alterations that confer increased susceptibility to targeted inhibition.

The company’s lead pipeline comprises several early-stage programs, including inhibitors designed to selectively disable DNA repair proteins in tumor cells while sparing normal tissues.